Heart-type, fatty-acid binding protein can be a diagnostic marker in acute coronary syndromes

Area of Science:

• Cardiology
• Biomarker Discovery
• Emergency Medicine

Background:

• Acute coronary syndrome (ACS) diagnosis relies on cardiac biomarkers like troponins, CK-MB, and myoglobin.
• These traditional markers often lack sensitivity in the early hours of ACS, delaying diagnosis.
• There is a need for more effective early diagnostic tools for chest pain evaluation.

Purpose of the Study:

• To evaluate the efficacy of heart-type fatty acid-binding protein (H-FABP) compared to CK-MB and myoglobin for the early diagnosis of ACS.
• To assess the sensitivity and specificity of H-FABP in the initial hours of suspected myocardial injury.

Main Methods:

• A study involving 67 patients diagnosed with ACS.
• Initial blood samples analyzed for CK-MB, troponin T (cTnT), myoglobin, and H-FABP.
• Serial ECGs and cardiac enzyme samples collected at 4, 8, and 12 hours post-admission.
• H-FABP levels were re-assessed at the 4-hour mark.

Main Results:

• H-FABP demonstrated high sensitivity (97.6%) in the first hour, comparable to CK-MB (96.7%) and superior to myoglobin (85.4%).
• H-FABP exhibited superior specificity (38.5%) at the first hour compared to CK-MB (34.6%), myoglobin (34.6%), and troponin T (23.1%).
• These performance trends for H-FABP were maintained up to the fourth hour of myocardial injury.

Conclusions:

• H-FABP is a sensitive and specific biomarker for the early diagnosis of ACS.
• Point-of-care H-FABP testing offers advantages of rapid, bedside results for patients presenting with chest pain.
• H-FABP measurement is recommended for patients with suspected ACS within 20 hours of symptom onset.